The Oncotype DX recurrence score (RS) is used as a tool for making decisions about chemotherapy for patients who have hormone receptor (estrogen receptor or progesterone receptor)-positive, HER2-negative breast cancer. There is no benefit from chemotherapy among patients aged ≥50 years who have lymph node-negative disease and an RS from 11 to 25, but the benefit of chemotherapy in the lymph node-positive group remains unknown. METHODS: On the basis of data from the National Cancer Data Base between 2010 and 2014, a nationwide, retrospective cohort study included 73,185 women who had stage I through IIIA breast cancer and an RS between 11 and 30. RESULTS: Receipt of chemotherapy was associated with a reduced risk of death among patients who had lymph node-positive breast cancer (hazard ratio [HR] 0.58; 95% confidence interval [CI], 0.45-0.74; P < .001) after adjusting for other prognostic factors in a multivariable Cox model. The 5-year survival gain ranged from 1.3% (RS 11-17 subgroup), to 3.3% (RS 18-25 subgroup), and to 6.7% (RS 26-30 subgroup). Among patients who had lymph node-negative disease, chemotherapy was associated with a reduced risk of death for those with an RS from 25 to 30 (HR, 0.68; 95% CI, 0.48-0.96; P = .03; 5-year survival gain, 1.8%), but there was no benefit from chemotherapy for patients who had an RS from 11 to 17 (HR, 0.97; 95% CI, 0.61-1.55; P = .90), and there was a marginally significant benefit for women who had an RS from 18 to 25 (HR, 0.79; 95% CI, 0.62-1.00; P = .05). Similar results were observed using propensity score-matching method. CONCLUSIONS: The benefit of chemotherapy for patients with breast cancer who have an intermediate RS is driven in a nonlinear fashion by RS: the higher the RS, the larger the absolute benefit. Findings from this study underscore the utility of real-world data to inform joint decision making in practice. 1 and the estimated 10-year to 15-year recurrence rate in these women after adjuvant chemotherapy is from 15% to 35%.
INTRODUCTION
Approximately 70% of newly diagnosed breast cancers are hormone receptor (estrogen receptor [ER] or progesterone receptor [PgR] )-positive, 1 and the estimated 10-year to 15-year recurrence rate in these women after adjuvant chemotherapy is from 15% to 35%. [2] [3] [4] On the basis of increasing knowledge of tumor heterogeneity and biologic mechanisms of resistance to systemic therapy, there is a need to develop and evaluate tools for the personalized treatment of hormone receptor-positive breast cancer to attain improved clinical outcomes with good quality of life.
The 21-gene recurrence score (RS) assay (Oncotype DX) (ODX) (Genomic Health, Redwood City, CA) was developed to guide treatment decisions based on prognostication of subsequent outcomes in clinical trials. 5 ODX has been validated in lymph node-negative and lymph node-positive patients as a prognostic tool using archival specimens from clinical trials with long-term follow-up. [5] [6] [7] [8] [9] [10] In practice, it is used by oncologists to counsel patients about the benefit of adding chemotherapy given the substantial benefit of hormone therapy in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. 11 The ODX results are expressed as a computed RS ranging from 0 to 100, with different cutoff points for low, intermediate, or high scores based on specified endpoints in prospective clinical trials or as generated by Genomic Health. 5, 12, 13 In the Trial Assigning Individualized Options for Treatment (TAILORx) clinical trial, which was designed to prospectively validate the RS in lymph node-negative breast cancer, the RS categories used were low risk (RS <11), intermediate risk , and high risk (RS >25). 12 Results from TAILORx demonstrated that patients with low-risk scores
Cancer January 15, 2019 (RS <11) who received hormone therapy alone experienced excellent clinical outcomes: the 5-year and 9-year rates of freedom from distant recurrence were 98.8% and 95.0%, respectively, whereas the overall survival rates at 5 years and 9 years were 98.0% and 93.7%, respectively. 14, 15 Recently, the TAILORx trial reported that the use of hormone therapy was noninferior to chemotherapy plus hormone therapy in patients who had had intermediate scores with lymph node-negative disease, and approximately 85% of women could be spared chemotherapy, especially those aged ≥50 years or aged <50 years with an RS <16. 15 Similarly, an initial report from the West German Study Group PlanB Study (WGS), an ongoing, prospective, phase 3 clinical trial that included patients with lymph node-positive breast cancer and an RS from 0 to 11, demonstrated excellent 3-year disease-free survival in those who received hormone therapy alone. 16 The RxPONDER trial is another ongoing, prospective, phase 3 study in which patients who have lymph node-positive disease with an RS ≤25 are randomized to receive endocrine therapy alone versus chemotherapy followed by endocrine therapy, but outcomes from that study are yet to be reported. 13 ODX has been adopted by oncologists in clinical practice using the following cutoff points from the company: an RS <18 is classified as low risk, an RS from 18 to 30 is classified as intermediate risk, and an RS >30 is classified as high risk. 5 Therefore, questions remain unanswered to inform the clinical decision for patients who have lymph node-positive and for those who have lymph node-negative disease with an RS from 26 to 30. A significant proportion of these patients may receive unnecessary adjuvant chemotherapy, whereas others may be undertreated by foregoing chemotherapy.
We used the largest data set to date to examine real-world data from the National Cancer Data Base (NCDB) on treatment outcomes among patients who were diagnosed with breast cancer and had an ODX RS in the intermediate range, defined as an RS from 11 to 30. The study takes advantage of ODX results, which were recently added as required data items in cancer registry operations nationwide in the United States and are suitably complete for valid interpretation. 17, 18 
MATERIALS AND METHODS

Data Source and Study Population
The NCDB (a joint project of the Commission on Cancer [CoC] of the American College of Surgeons and the American Cancer Society) is a nationwide, facilitybased, oncology data set that includes information on approximately 70% of all incident cancers diagnosed in the United States collected from more than 1400 hospitals participating in the American College of Surgeons CoC. 19 Routinely collected data items include patient demographics, tumor characteristics (such as tumor site and histology), and American Joint Committee on Cancer stage. 20, 21 The current study used de-identified data and was deemed exempt from human protection oversight by the Institutional Review Board of the University of Chicago. We identified 1,092,106 patients who were diagnosed with breast cancer from January 1, 2010 to December 31, 2014 , in the NCDB. The study was limited to women aged ≥18 years who were diagnosed with stage I to IIIA, first primary, hormone receptor (ER or PgR)-positive, HER2-negative breast cancer (according to American Society of Clinical Oncology/College of American Pathologists guidelines 22 ) who received all or part of their first course of treatment in the reporting facility. We included patients who had an RS from 11 to 30. We further excluded patients who had data missing for hormone receptor status, chemotherapy receipt, survival, the number of positive lymph nodes, and ODX test results. After these selections, 73,185 patients were included in the final analysis (Supporting Fig. 1 ).
Study Variables
In the primary analysis, the RS was analyzed as a categorical variable at prespecified cutoff points (scores of 11-17, 18-25, and 26-30) . This subdivision was used to accommodate the classification of intermediate RS both in the ongoing clinical trials (scores of [17] [18] [19] [20] [21] [22] [23] [24] [25] 12,13,16 and in the current clinical practice . Patients were further stratified according to lymph node status (positive vs negative). The RS also was analyzed as a continuous variable using a restricted cubic spline (RCS) function with 3 knots at scores of 12, 17, and 25. Spline functions are piecewise polynomials used in curve fitting and possess smoothness at the places where the polynomial pieces connect (known as knots). A spline represents a less biased and efficient method of modeling the shape of continuous covariates.
Patient demographics, including age at diagnosis and race, were analyzed as categorical variables. Patient comorbidity status was represented by the adoption by Deyo et al of the Charlson comorbidity index (CCI), 23 which is a cumulative score of 15 health conditions. Tumor characteristics, including tumor size, lymph node involvement, grade, histologic type, and PgR status, were analyzed as categorical variables. The first courses of chemotherapy and hormone therapy and their status were recorded, but specific types of Cancer January 15, 2019 chemotherapy and hormone therapy were not available in the NCDB. Data on ovarian suppression were not recorded in the NCDB.
Statistical Analysis
Demographic and tumor characteristics were compared between patients who did and did not receive chemotherapy using chi-square tests. To evaluate the prognostic value of the RS, we modeled the relation between RS and overall survival using Cox proportional hazard models stratified by lymph node status. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated from Cox models. Linearity of the prognostic effect of RS was tested by comparing the model in which RS was fitted with a simple linear function and the model in which RS was fitted with RCS functions.
We examined the predictive effect of the RS in 4 steps. First, we compared patients who received chemotherapy (plus hormone therapy) versus those who did not receive chemotherapy (hormone therapy alone) separately in lymph node-positive and lymph node-negative patients using multivariable Cox models adjusting for age, year of diagnosis, CCI, race/ethnicity, tumor size, histology, grade, PgR status, lymphovascular invasion, and RS. We calculated the HR as a metric of relative risk. To facilitate clinical interpretation, we estimated marginal cumulative mortality risks and absolute risk differences from the fitted Cox models. The marginal mortality risk can be interpreted as the population average risk if all patients received or did not receive chemotherapy, while keeping all other prognostic factors unchanged for each patient. Second, we further stratified the patients into prespecified RS subgroups (scores of 11-17, 18-25, and 26-30), because we hypothesized that the intermediate group is heterogeneous and that the relative/absolute benefit of chemotherapy varies by RS subgroup. This was the primary analysis. Multivariable Cox models similar to those constructed in step 1 were fitted. Third, we fit multivariable Cox models that included an interaction term of continuous RS and chemotherapy to explore the range of the RS in which chemotherapy is effective. The RS was modeled using the aforementioned RCS functions. Finally, as a sensitivity analysis, we conducted a propensity score matching. A propensity score was the log odds of receiving chemotherapy estimated from the logistic regression that included RS, the number of positive lymph nodes, an interaction term of RS and lymph node status, age, year of diagnosis, CCI, race/ethnicity, tumor size, histology, grade, PgR, and lymphovascular invasion. Before and after 1:1 matching, we checked the standardized differences between patients who did and did not receive chemotherapy to examine whether matching on the propensity score removed the observed differences. 24 After the matching, we estimated survival rates using the Kaplan-Meier method and calculated HRs from Cox models in the 6 prespecified subgroups (lymph node status by RS category). A 2-sided P value < .05 was considered statistically significant. Statistical analyses were conducted using the STATA 14 software package (StataCorp, College Station, TX).
RESULTS
Distribution of the RS and Chemotherapy
Between 2010 and 2014, 125,556 women who were diagnosed with stage I through IIIA hormone receptorpositive breast cancer received ODX as clinically indicated, and 106,439 women had exact RS results. Of these, 73,185 patients (68.8%) had an intermediate ODX score (RS 11-30), 24,372 (22.9%) had an RS from 0 to 10, and 8882 (8.3%) had an RS from 31 to 100. Figure 1 presents the distribution of RS results and the receipt of chemotherapy. Table 1 provides demographic and clinical characteristics of the patients who had intermediate RS according to the 3 RS subgroups. Twenty-four percent of patients were aged <50 years, 82% patients had lymph node-negative disease, 75% had tumor size ≤2 cm, and 24% received chemotherapy. Factors strongly associated with higher RS were higher tumor grade and negative PgR status. Otherwise, most clinical characteristics were distributed fairly across the subgroups. Patients who had an RS from 26 to 30 (66.6%) were more likely to receive chemotherapy than those who had an RS from 18 to 25 (34.6%) and those who had an RS from 11 to 17 (9.0%). Other strong indicators for receiving chemotherapy included the presence of lymph node disease, younger age, larger tumor, higher tumor grade, lymphovascular invasion, and clinical high risk, which was defined according to the by MINDACT ("Microarray in Node-Negative and 1-3 Positive Lymph Node Disease May Avoid Chemotherapy") modification of Adjuvant!Online 25 (Supporting Table S1 ). There was a decreasing trend of chemotherapy use between 2010 and 2014.
Prognostic Value of the RS on Overall Survival
Over a median follow-up of 41 months, 1450 patients died. The RS in the intermediate range was highly prognostic for both lymph node-positive and lymph node-negative breast cancers when it was examined as Cancer January 15, 2019 a continuous variable (Fig. 2 ). There was a monotonic increasing trend between RS and mortality risk, but the trend was not linear (test for linearity; P = .03). The risk of mortality in patients who had lymph node-negative tumors increased by 1% per 1-unit RS increment of in the RS 11 to 17 category (P = .61) and by 6% per 1-unit RS increment in the RS 18 to 30 category (P < .001). In lymph node-positive patients, the risk of mortality increased by 2% per 1-unit increment of RS in the RS 11 to 17 category (P = .39) and 9% per 1-unit RS increment in the RS 18 to 30 category (P < .001). Lymph node status also was a strong prognostic factor regardless of the RS (Fig. 2) . Furthermore, we observed that the prognostic value of RS was stronger in women aged ≤50 years than in those aged >50 years (Supporting Fig. 2 ). Other prognostic factors for overall mortality included age, race/ethnicity, the number of positive lymph nodes, tumor size, histologic grade, lymphovascular invasion, CCI, and clinical risk group defined by the MINDACT trial (Supporting Table 2 ).
Predictive Effect of the RS on Chemotherapy Use
Next, we examined the effect of chemotherapy on mortality using multivariable Cox models within lymph nodepositive or lymph node-negative patients and within the 6 prespecified strata defined by lymph node status and RS subgroups ( Table 2) . After adjusting for multiple covariates, we observed that the receipt of chemotherapy had a statistically significant association with better survival in patients who had lymph node positive-breast cancer as a whole (HR, 0.58; 95% CI, 0.45-0.74; P < .001), and this protective effect was significant in all 3 RS subgroups, although the relative reduction was slightly larger for the RS 26 to 30 subgroup. In patients who had lymph nodenegative disease, chemotherapy was significantly associated with survival only for the RS 26 to 30 subgroup (HR, 0.68; 95% CI, 0.48-0.96; P = .03). There was no benefit of chemotherapy in patients who had lymph node-negative disease with an RS from 11 to 17 or from 18 to 25, consistent with recent data from the TAILORx trial. In patients who had lymph node-negative disease with an RS from 11 to 25, there was no significant interaction between chemotherapy and age (≤50 vs >50 years) for overall survival (P = .59) (Supporting Table 3 ). To better interpret the clinical benefit of chemotherapy, we calculated the multivariable-adjusted absolute risk difference in patients who received chemotherapy compared with those who did not (Fig. 3) . The 5-year survival gain from chemotherapy varied substantially across subgroups, from no benefit for patients who had lymph node-negative disease and an RS from 11 to 17 (0.1%) to large benefit for those who had lymph node-positive disease and an RS from 26 to 30 (6.7%).
To explore the effect of chemotherapy as a function of the RS, we modeled RS as a continuous variable using a RCS function. We determined that, in lymph node-negative patients, the benefit from chemotherapy was observed if the RS was ≥23; whereas, in lymph node-positive patients, the benefit from chemotherapy was observed if the RS was >13 (Fig. 4) . This analysis suggests that our predefined RS subgrouping is appropriate. Stratified by age, we did not observe that the effect of chemotherapy varied by age (Supporting Fig. 3 ). Cancer January 15, 2019 In an alternative approach to remove confounding, we conducted a propensity score-matching analysis. In total, 13,735 patients who received chemotherapy were matched with 13,735 who did not receive chemotherapy. Supporting Table 4 indicates that the 2 groups were quite balanced in terms of demographics and tumor characteristics after the matching. We reassessed the effectiveness of chemotherapy using the matched cohort and observed that the effect estimates were similar to those observed in the multivariable models, which used the full cohort although the CIs were wider using the matched cohort (Supporting Table 5 , Supporting Fig. 4) . The sample size in the lymph node-positive RS 26 to 30 subgroup was limited (26 events), so the effect did not reach statistical significance.
DISCUSSION
Over the last decade, there has been an upward trend in the use of ODX. Approximately 50% of patients who are diagnosed with early stage, hormone receptorpositive breast cancer now receive ODX testing, and more than one-third of those patients reportedly have intermediate ODX scores . 26 Similarly, we observed that one-third of patients had an RS from 18 to 30, and another one-third had an RS from 11 to 17. Because the new American Joint Committee on Cancer eighth edition cancer staging system incorporates prognostic/predictive gene markers like ODX, 27 a rapid rise in its clinical utility is expected. Therefore, it becomes imperative to have a more defined approach to addressing patients with intermediate ODX scores. We observed an absolute benefit of chemotherapy that increased incrementally with rising RS, with larger absolute benefits for patients with lymph node-positive disease. These findings become relevant in clinical decision making. Our study adds new knowledge addressing the question of the benefit of chemotherapy in lymph node-negative and lymph node-positive patients who have intermediate RS from 11 to 30 using a large, nationwide data set.
The prognostic value of ODX was validated by the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14 trial, which retrospectively demonstrated that, in lymph node-negative women, a higher RS was associated with an elevated 10-year risk of recurrence when the whole range of RS (0-100) was analyzed, 5 and the prognostic value of the RS has been reproduced by other studies over the years. 6, 28 Consistent with previous studies, our study demonstrated that, the higher the RS, the higher the risk of mortality for patients with intermediate RS. Mortality risk differed for patients with regard to the presence or absence of lymph node disease, and this Cancer January 15, 2019 finding was consistent with the retrospective analysis by the Southwest Oncology Group (SWOG) trial 8814 and a study of Surveillance, Epidemiology, and End Results registries, which demonstrated that a higher RS was associated with poorer overall survival and breast cancer-specific survival in lymph node-positive patients. 7, 18 Cancer January 15, 2019
The predictive value of ODX in lymph nodenegative patients was established by the NSABP B-20 trial, which indicated that the benefit of chemotherapy was greatest if the RS was >30, with an HR of 0.26, whereas a nonsignificant effect was observed in the intermediate-risk group (RS 18-30; HR, 0.61; 95% CI, 0.24-1.59), and no benefit was observed in the low-risk group (RS <18; relative risk, 1.31). 9 The prospective TAILORx trial reported that hormone therapy was noninferior to hormone therapy plus chemotherapy for patients in the RS 11 to 25 group (invasive DFS: HR, 0.96; 95% CI, 0.81-1.06; overall survival: HR, 1.01; 95% CI, 0.82-1.27). 15 We also observed that chemotherapy had no significant protective effect on overall survival in patients who had an RS from 11 to 25. In our study, the 5-year adjusted mortality risk was 3.0% in the hormone therapy group and 2.6% in the hormone therapy plus chemotherapy group, both of which were slightly higher than that reported in the TAILORx trial (2.0% and 1.9%, respectively). 15 The TAILORx investigators reported an interaction between age and RS category for invasive DFS, but not for overall survival. For the current study, we used overall survival as the study endpoint and did not identify any differential effects by age, suggesting that overall survival cannot capture this interactive effect. In the TAILORx trial, all patients who had an RS from 26 to 30 were assigned to chemoendocrine therapy, and the 5-year mortality risk was 4.1%. Our results indicate that chemotherapy has a significant protective effect on patients in the RS 26 to 30 subgroup, and their 5-year adjusted mortality risk was 4.2% in the chemoendocrine therapy group.
The predictive value of ODX was not clear for patients who had lymph node-positive disease with an intermediate RS. The retrospective analysis of breast tissue samples in the SWOG 8814 study, which was conducted in lymph node-positive patients, did not report a statistically significant benefit of chemotherapy in patients who had an RS from 18 to 30 (HR, 0.72; 95% CI, 0.31-1.31), with the caveat that the sample size was small. 7 In contrast, we observed a statistically significant protective effect of chemotherapy for patients in the RS 11 to 30 subgroup (HR, 0.58; 95% CI, 0.45-0.74), and, more important, the absolute benefits varied according to RS. The identification of significant effects in our study could be because of our larger sample size (376 deaths) compared with the SWOG 8814 study (42 events). Other possible reasons include improvements in supportive care during chemotherapy and differences in chemotherapy regimens. Patients in earlier studies used the CMF (cyclophosphamide, methotrexate, 5-fluorouracil) regimen, whereas therapies used in the contemporary cohort in our study are likely to be doxorubicin-based or taxane-based regimens according to National Comprehensive Cancer Network guidelines and the literature. 29 In advance of the publication of the RxPONDER trial in lymph node-positive patients, 13 our current findings suggest that some lymph node-positive patients with intermediate RS derive benefit from chemotherapy or participation in clinical trials that test novel, targeted treatments. Future studies could be conducted to investigate whether chemotherapy is beneficial for patients with lymph node-positive breast cancer with an RS from 0 to 10.
There are several strengths to this study, including a large, nationwide sample with sufficiently complete data on ODX for the years of analysis and refined subgroup analysis. The study also has several limitations. Cancer January 15, 2019 First, observational studies are subject to confounding. We used multivariable Cox models to control for known variables related to the receipt of chemotherapy, and we conducted propensity score matching to remove potential confounding. However, unmeasured confounders still may exist. Because we identified differential effects of chemotherapy across lymph status and RS subgroups, unmeasured confounders, if they exist, have to play a differential role across subgroups. Furthermore, our study findings in lymph node-negative patients are consistent with those from the recently published, randomized TAILORx trial. Second, the NCDB collects data from CoC-accredited hospitals, which are larger, more frequently located in urban locations, and have more cancer-related services than non-CoC hospitals. 20 Hence, our findings may be limited to CoC-approved hospitals, but clinical trials also tend to occur in CoC-approved hospitals and have similar limitations. Third, the follow-up of the patients was short, so our study could only assess the short-term effects of chemotherapy and the RS, but any benefit from chemotherapy is expected to be detected up early. 30, 31 Although a previous study indicated that the RS is better at predicting short-term survival than longterm survival, 7 further follow-up of this national cohort is warranted. Fourth, exact chemotherapy regimens were not available in the NCDB, which makes the interpretation of the study findings somewhat difficult, although doxorubicin-based or taxane-based regimens are likely in this contemporary cohort. 29 Because most of the benefit of chemotherapy occurs during the first few years after diagnosis, 30 ,31 the optimal adjuvant treatment regimen for reducing the risk of late recurrences in patients with ER-positive breast cancer is unknown. Nonetheless, this study has demonstrated the benefits of chemotherapy according to the RS and lymph node status, but the 5-year survival benefit of 1% to 7% needs to be balanced with the known, long-term, adverse effects of chemotherapy, which reportedly range from 2% to 27%, especially in patients who have other comorbidities such as hypertension, diabetes, and obesity. [32] [33] [34] In the current cohort, 17,858 patients (24.4%) in the intermediate RS subgroup actually received chemotherapy. If we consider that a 5-year gain of 1% in absolute survival benefit is clinically acceptable, then 9191 patients (12.6%) with an intermediate RS have been treated appropriately, 8667 patients (11.8%) may have been over-treated, and 9902 patients (13.5%) could have been under-treated.
In summary, the current study demonstrates that a careful analysis of real-world data can provide valid results, which often are complementary to those obtained in randomized clinical trials. These findings provide additional data that can be used to inform clinical decision making and underscore the need for further studies to optimize treatment in women with ER-positive breast cancer.
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